Boston An independent LDT provider

Dr. Thomas King Invited as Keynote Speaker by NCI

November 1, 2021

Immunovia, Inc.’s Medical Director, Dr. Thomas King, Invited as Keynote Speaker by US National Cancer Institute

LUND, SWEDEN – Immunovia AB (publ) (“Immunovia”), a diagnostic company that develops and sells highly accurate blood tests for the early detection of cancer, today announced that Thomas King, MD, PhD, Medical Director of Immunovia, Inc. was invited to present to the U.S. National Cancer Institute (NCI) Pancreatic Cancer Detection Consortium (PCDC) as a keynote speaker at their upcoming Steering Committee Meeting, taking place virtually on December 13-14, 2021.

Dr. Thomas King’s keynote presentation will focus on Immunovia’s recent progress on the early detection of pancreatic cancer and the study results for the IMMray™ PanCan-d test. Immunovia’s IMMray™ PanCan-d test is the world’s first blood test dedicated to early detection of pancreatic cancer. It is available as a laboratory developed test in the US exclusively through Immunovia, Inc.

“We are very excited to participate in this NCI sponsored program since we feel that robust biomarkers such as those contained in the IMMray™ PanCan-d test represent the best current opportunity to impact the survival of PDAC patients by detecting tumors at an early stage when they are potentially resectable,” said Dr. Thomas King.

The main objective of the PCDC is to “develop and test new molecular and imaging biomarkers to improve the detection of early-stage pancreatic ductal adenocarcinoma (PDAC) and its precursor lesions and identify individuals who are at high risk of developing PDAC and are candidates for early intervention.”

There are eight PCDC teams focused on this objective, with Principal Investigators from leading pancreatic cancer academic centers around the US.

For more information, please contact:
Patrik Dahlen, CEO Immunovia
Email: patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64